Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Show more
Location: 19800 MacArthur Boulevard, Irvine, CA, 92612, United States | Website: https://eledon.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
155.1M
52 Wk Range
$2.38 - $5.54
Previous Close
$2.55
Open
$2.56
Volume
853,636
Day Range
$2.54 - $2.65
Enterprise Value
48.33M
Cash
107.6M
Avg Qtr Burn
-16.13M
Insider Ownership
1.40%
Institutional Own.
72.25%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tegoprubart (AT-1501) Details Type 1 diabetes, Islet Cell Transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Kidney transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Amyotrophic lateral sclerosis | Phase 2 Update | |
Tegoprubart (AT-1501) Details Kidney transplantation | Phase 1b Update | |
Tegoprubart (AT-1501) Details Autoimmune nephritis | Failed Discontinued | |
Tegoprubart (AT-1501) Details IgA nephropathy | Failed Discontinued |